Skip to main content

Arena Pharmaceuticals, Inc. (ARNA)

NASDAQ: ARNA · IEX Real-Time Price · USD
60.08 -1.00 (-1.64%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap3.67B
Revenue (ttm)57,000
Net Income (ttm)-484.11M
Shares Out60.79M
EPS (ttm)-8.18
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume393,873
Open60.72
Previous Close61.08
Day's Range59.55 - 61.31
52-Week Range45.50 - 90.19
Beta0.49
AnalystsStrong Buy
Price Target95.25 (+58.5%)
Est. Earnings DateNov 8, 2021

About ARNA

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the tr...

IndustryBiotechnology
IPO DateJul 28, 2000
CEOAmit Munshi
Employees363
Stock ExchangeNASDAQ
Ticker SymbolARNA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for ARNA stock is "Strong Buy." The 12-month stock price forecast is 95.25, which is an increase of 58.54% from the latest price.

Price Target
$95.25
(58.54% upside)
Analyst Consensus: Strong Buy

News

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 20 new employees inducem...

1 week ago - Business Wire

7 Busted Biotech Stocks Due for a Rebound

Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on In...

Other symbols:AMRNARCTBLUESAVATBPH
2 weeks ago - InvestorPlace

Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena to host two virtual R&D Investor calls for analysts and investors focused on etrasimod programs in gastroenterology and dermatology.

3 weeks ago - Business Wire

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PARK CITY, Utah--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement stock options, inducement perfor...

1 month ago - Business Wire

Arena Pharmaceuticals, Inc. (ARNA) Reports Q2 Loss, Lags Revenue Estimates

Arena Pharmaceuticals, Inc. (ARNA) delivered earnings and revenue surprises of -8.60% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the st...

1 month ago - Zacks Investment Research

Arena Reports Second Quarter Financial Results and Key Program Updates

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals (Nasdaq: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

1 month ago - Business Wire

Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers

BRISBANE, Calif., Aug. 5, 2021 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform sg-4-sight to discover and develop precision therapies and biomarkers from p...

1 month ago - PRNewsWire

Arena Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Corporate Update on August 5

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena will release second quarter 2021 financial results and provide a corporate update on August 5, after the close of the U.S. financial markets.

1 month ago - Business Wire

Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of S...

PARK CITY, Utah, & SAN DIEGO--(BUSINESS WIRE)---- $ARNA #ARNA--Strategic collaboration and option agreement provides Arena with exclusive option to acquire Aristea and its CXCR2 programs post-Phase 2.

1 month ago - Business Wire

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on July 16, 2021, the Compensation Committee of its Board of Directors granted to 17 new...

2 months ago - Business Wire

Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals announces the appointment of Douglas J. Manion, M.D., F.R.C.P. (C), as EVP of Research & Development.

2 months ago - Business Wire

Pot Stocks in Focus: Cannabis-Based Pharmaceutical Trials

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...

3 months ago - Schaeffers Research

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on June 15, 2021, the Compensation Committee of its Board of Directors granted to 17 new...

3 months ago - Business Wire

Breaking Down a Wild Week in the World of Weed Stocks

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...

3 months ago - Schaeffers Research

Steven Schoch Elected to Arena Pharmaceuticals Board of Directors

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Steven Schoch, CFO of 23andMe, appointed to Arena Pharmaceuticals' Board of Directors and as Chair of the Audit Committee.

3 months ago - Business Wire

Smoked! How the Hottest Cannabis Stocks Fared This Week

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...

3 months ago - Schaeffers Research

Arena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE

The FDA bestows an Orphan Drug status to Arena's (ARNA) lead pipeline candidate, etrasimod, for the treatment of eosinophilic esophagitis.

3 months ago - Zacks Investment Research

Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel

Arena (ARNA) is developing temanogrel in a phase II study as potential treatment for coronary microvascular obstruction in patients undergoing percutaneous coronary intervention.

3 months ago - Zacks Investment Research

Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (...

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to etra...

3 months ago - Business Wire

Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Micro...

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena announces first participant randomized in Phase 2 trial evaluating IV temanogrel for the potential treatment of cMVO in patients undergoing PCI.

3 months ago - Business Wire

Why Is Arena Pharmaceuticals, Inc. (ARNA) Down 2.8% Since Last Earnings Report?

Arena Pharmaceuticals, Inc. (ARNA) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

Breaking Down a Busy Week of Weed Stocks

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...

3 months ago - Schaeffers Research

Arena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals today announced that as of 2021, Arena received an MSCI ESG Rating of "A."

3 months ago - Business Wire

6 Cannabis Stocks Lighting Up the News This Week

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...

Other symbols:ACBCGCIIPRNEPTOGI
4 months ago - Schaeffers Research

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on May 15, 2021, the Compensation Committee of its Board of Directors granted to 22 new ...

4 months ago - Business Wire